<DOC>
	<DOCNO>NCT01382940</DOCNO>
	<brief_summary>This study design evaluate safety administer rituximab rapid infusion rate patient moderate severe rheumatoid arthritis inadequate response biopharmaceuticals treat disease interfere tumor necrosis factor ( anti-TNF therapy ) , receive methotrexate therapy eight week .</brief_summary>
	<brief_title>A Study The Safety Administering Rituximab A More Rapid Rate Patients With Rheumatoid Arthritis</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
	<mesh_term>Prednisolone</mesh_term>
	<mesh_term>Prednisolone acetate</mesh_term>
	<mesh_term>Methylprednisolone acetate</mesh_term>
	<mesh_term>Methylprednisolone</mesh_term>
	<mesh_term>Prednisolone hemisuccinate</mesh_term>
	<mesh_term>Prednisolone phosphate</mesh_term>
	<mesh_term>Acetaminophen</mesh_term>
	<mesh_term>Histamine Antagonists</mesh_term>
	<mesh_term>Histamine H1 Antagonists</mesh_term>
	<criteria>Key Adult patient , ≥ 18 year age Rheumatoid arthritis ≥ 6 month duration , diagnose accord revised 1987 American College Rheumatology criterion Inadequate response least one approve antiTNF agent ( adalimumab , etanercept , infliximab , golimumab , certolizumab ) Patients received 1 2 prior course rituximab ( RTX ) may enrol , provide recent course RTX occur 6 month 9 month prior baseline . The RTX dosage must two 1000 mg infusion per course administer standard approve rate Methotrexate treatment 10 25 mg/week ( oral parenteral ) least 8 week immediately prior baseline Key Major surgery ( include joint surgery ) within 8 week prior screen plan surgery within 6 month follow baseline Rheumatic autoimmune disease rheumatoid arthritis Functional class IV define American College Rheumatology ( ACR ) criteria Prior history current inflammatory joint disease rheumatoid arthritis History severe allergic anaphylactic reaction human , humanized murine monoclonal antibody Previous serious infusion reaction prior biologic therapy Known active current history recurrent infection Evidence chronic hepatitis B C infection Pregnant lactate woman Body weight &gt; 150 kg</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2014</verification_date>
</DOC>